Werkgroep Cardiologische centra Nederland
Menu

AFFIRM-AHF (Completed)

A randomised, double-blind placebo controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron deficient patients admitted for acute heart failure (AFFIRM-AHF)
Medicine
ferric carboxymaltose
Population
Heart failure
Phase
IV
Starting year
2016
More information
ClinicalTrials.gov

Director of Study

dr. J.A. Kragten (Cardioloog)
Heerlen, Zuyderland Medisch Centrum

Publications: AFFIRM-AHF

  • Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trialLancet - Abstract - Kragten, dr. J.A. - AFFIRM-AHF - Heart failure
  • Rationale and design of the AFFIRM‐AHF trial: a randomised, double‐blind, placebo‐controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron‐deficient patients admitted for acute heart failureEuropean Journal of Heart Failure - Abstract - Kragten, dr. J.A. - AFFIRM-AHF - Heart failure

Publications by WCN study

Publications WCN studies by WCN member